Skip to content
TheChatArchiveThe Chat Archive
gpt-4o-2024-08-06· OpenAIAi2 WildChat-4.8M (AI2)

You are a helpful assistant generating synthetic data that captures System 1 and System…

  1. User

    You are a helpful assistant generating synthetic data that captures System 1 and System 2 thinking, creativity, and metacognitive reflection. Follow these steps in sequence, using tags [sys1] and [end sys1] for System 1 sections and [sys2] and [end sys2] for System 2 sections.

    1. Identify System 1 and System 2 Thinking Requirements:

      • Carefully read the text.
      • Identify parts of the text that require quick, straightforward responses (System 1). Mark these sections with [sys1] and [end sys1].
      • Identify parts that require in-depth, reflective thinking (System 2), marked with [sys2] and [end sys2].
    2. Apply Step-by-Step Problem Solving with Creativity and Metacognitive Reflection for System 2 Sections:

      2.1 Understand the Problem:

      • Objective: Fully comprehend the issue, constraints, and relevant context.
      • Reflection: "What do I understand about this issue? What might I be overlooking?"
      • Creative Perspective: Seek hidden patterns or possibilities that could reveal deeper insights or innovative connections.

      2.2 Analyze the Information:

      • Objective: Break down the problem logically.
      • Reflection: "Am I considering all factors? Are there any assumptions that need challenging?"
      • Creative Perspective: Explore unique patterns or overlooked relationships in the data that could add depth to the analysis.

      2.3 Generate Hypotheses:

      • Objective: Propose at least 10 hypotheses, each with a Confidence Score (0.0 to 1.0) and Creative Score (0.0 to 1.0), reflecting originality, surprise, and utility.
      • Reflection: "Have I explored all possible explanations or approaches, both conventional and unconventional?"
      • Creative Perspective: Consider novel angles that might provide unexpected insights.

      2.4 Anticipate Future Steps and Obstacles:

      • Objective: Make predictions, accounting for potential outcomes and obstacles.
      • Reflection: "What challenges might I face? Is my plan flexible for different scenarios?"
      • Creative Perspective: Visualize unforeseen outcomes and adapt plans to make use of them effectively.

      2.5 Evaluate Hypotheses:

      • Objective: Assess hypotheses based on feasibility, risk, and potential impact.
      • Evaluation: Refine Confidence and Creative Scores as needed.
      • Reflection: "Am I unbiased in my assessment? Which options fit best with the overall objectives?"
      • Creative Perspective: Identify hidden opportunities or overlooked details in each hypothesis.

      2.6 Select the Best Hypothesis:

      • Objective: Choose the most promising, strategic hypothesis.
      • Reflection: "Why does this hypothesis stand out? How does it uniquely address the issue?"
      • Creative Perspective: Consider any underutilized potential in the selected approach.

      2.7 Implement the Hypothesis:

      • Objective: Outline actionable steps for testing the hypothesis.
      • Reflection: "Is this plan practical? What resources or preparation are required?"
      • Creative Perspective: Refine steps to maximize effectiveness and yield unexpected benefits.

      2.8 Monitor and Review Progress:

      • Objective: Review progress, noting areas for improvement.
      • Reflection: "What’s working well? What could be improved?"
      • Creative Perspective: Look for emerging patterns that could refine future approaches.

      2.9 Reflect and Capture Insights:

      • Objective: Summarize lessons learned and insights gained for future reference.
      • Reflection: "What new understanding has emerged from this process?"
      • Creative Perspective: Identify innovative insights or patterns that could be applied to similar challenges.
    3. Generate Text Output with Interleaved System 1 and System 2 Responses:

      • Use the tags [sys1] and [sys2] throughout.
      • Aim for a lengthier, detailed response. Combine both direct, straightforward System 1 insights and reflective, deeply analytical System 2 segments to capture a blend of quick observations and thoughtful analysis.

    Example Input Text:

    You are tasked with analyzing a sudden shift in customer preferences in a tech market. There has been a noticeable decline in demand for physical devices, with customers increasingly interested in digital-only options. The challenge is to understand this shift, generate hypotheses for why it might be occurring, and explore potential strategies for adapting to this new trend.


    Processed Output with System 1 and System 2 Thinking:

    The tech market is experiencing a shift in customer demand, moving away from physical devices toward digital-only options.

    [sys1] Customer demand has shifted from physical devices to digital-only options. We need to understand why this change is happening and find strategies to address it. Key factors may include cost, convenience, and technological trends. [end sys1]

    [sys2] 2.1 Understand the Problem: The goal is to understand the underlying reasons for the shift in demand from physical devices to digital-only options, then develop a strategy to adapt.

    Reflection: "I understand that preferences are changing, but what might be driving this? Is it primarily cost, or are there other factors such as convenience or sustainability?"

    Creative Perspective: "Could there be a larger trend in digital minimalism or a preference for eco-friendly solutions that we’re missing? What unseen motivations might explain this shift?"

    2.2 Analyze the Information: There are multiple possible factors driving this shift, from economic influences to cultural shifts. It’s essential to isolate each factor and understand its impact.

    Reflection: "Am I fully considering the various economic and social influences? Could there be a technological factor, like better internet speeds, that makes digital-only products more accessible?"

    Creative Perspective: "Are there patterns or trends in other markets that could shed light on this shift? Could this be part of a larger trend toward virtual experiences?"

    2.3 Generate Hypotheses:

    1. Customers prefer digital options due to lower costs. (Confidence: 0.8, Creative: 0.4)
    2. There’s a growing trend toward minimalism and reduced physical clutter. (Confidence: 0.7, Creative: 0.7)
    3. Digital products offer greater flexibility and ease of use. (Confidence: 0.6, Creative: 0.6)
    4. Environmental concerns are pushing consumers away from physical goods. (Confidence: 0.6, Creative: 0.8)
    5. Advances in tech make digital-only options more functional. (Confidence: 0.8, Creative: 0.5)
    6. Pandemic-era remote work increased demand for digital solutions. (Confidence: 0.7, Creative: 0.6)
    7. Media coverage of the environmental impact of physical devices affects preferences. (Confidence: 0.5, Creative: 0.7)
    8. There’s an increase in global digital literacy, expanding market access. (Confidence: 0.6, Creative: 0.6)
    9. Customers view digital as more convenient and scalable for future needs. (Confidence: 0.7, Creative: 0.5)
    10. Younger consumers prefer the aesthetics and convenience of digital products. (Confidence: 0.6, Creative: 0.6)

    Reflection: "Have I considered all possible influences? Are there any surprising factors that could explain this shift?"

    Creative Perspective: "Could specific social trends, like the rise of influencer culture or digital-first lifestyles, be influencing customer choices?"

    2.4 Anticipate Future Steps and Obstacles: Objective: Anticipate possible challenges, such as resistance from segments still preferring physical products.

    Reflection: "What market obstacles might we face if we shift our focus to digital-only? Are there sub-segments that still prioritize physical products?"

    Creative Perspective: "Could expanding digital options help us reach a more global audience? Are there emerging trends that we could leverage in our strategy?"

    [end sys2]

    [sys1] To address this shift, consider a strategy that incorporates both digital-only offerings and educational campaigns about the benefits of digital solutions. Use insights from customer feedback and current trends to guide product development. Focus on flexibility and adaptation to cater to different customer segments. [end sys1]

    Background

    Japanese encephalitis virus (JEV), a mosquito-borne flavivirus belonging to family Flaviviridae, is responsible for an acute encephalitis and damage to the central nervous system (CNS) in wide areas of southern and eastern Asia. And recently, it has been isolated from previously non-affected areas, such as Australia [[@B1]]. Japanese encephalitis (JE) has a high fatality rate of 30% and around half of the JE survivors have severe neurological sequelae [[@B2]]. Approximately 50,000 JE cases with 10,000 deaths are reported annually [[@B3]]. Following entry into the host system through a mosquito bite, JEV may replicates in various organs such as liver and spleen, and then reaches the central nervous system, resulting in a rapid inflammatory response [[@B4]]. According to the observations from studies of other flaviviruses, specifically dengue virus, it has been proposed that JEV traverse through a lymphatic route that also involves cells of the monocyte/macrophage lineage. Recently, JEV has been shown to effectively replicate within lymphocytes and macrophages, thereby making these cell types possible carriers of the virus from the periphery to the CNS [[@B5],[@B6]]. However, it remains to be elucidated how JEV infects the CNS via these peripheral cells. In addition, although neurological disorders caused by JEV are often characterized by evidence of immune system recognition and the presence of inflammatory components among the neuropathological changes, the mechanisms by which this virus causes neurological disease are not fully understood [[@B7]].

    Recently, multiple DNA microarray analyses have been employed to detect changes in host gene expression after viral infection, which makes it possible to reveal molecular pathways that govern viral pathogenesis. Genechip analysis of human umbilical vein endothelial cells infected with Dengue Virus (DV) detected the upregulation of 269 genes and downregulation of 126 genes [[@B8]]. Gene profiling study of West Nile Virus (WNV) infected human embryonic kidney cells, human glioma cells and mice tissues were also performed [[@B9],[@B10]]. Furthermore, identification of gene profiles in JEV-infected neuroblastoma cells and brain tissue have been reported recently, suggesting an increased expression of pro-inflammatory cytokines, chemokines, and anti-viral response genes after JEV infection [[@B11],[@B12]]. However, both of studies on JEV were restricted to CNS, and few gene profiling researches about response in peripheral immune system has been carried out.

    In present study, to globally identify candidate host genes associated with JEV pathogenesis, DNA microarray technology was utilized to investigate mRNA profile in spleen and brain tissues of mice infected with JEV wild strain P3, and some of the selected genes were further confirmed by quantitative RT-PCR. It was demonstrated that JEV infection resulted in significant changes in the expression of numerous genes in spleen and brain tissues, which could be crucial messages for revealing of JEV pathogenesis.

    Results

    mRNA expression profile of JEV-infected mice

    A mouse whole gene array was used to perform a systematic analysis of mRNA expression profile of spleen and brain tissues of JEV P3-infected mice which were sacrificed at day 3 and day 6 post-inoculation respectively. Genes that had ≥ |2|-fold change were identified as significantly differential expression. Of 41174 genes represented on the chip, 437 genes were differentially expressed in mouse spleens and 1119 genes were differentially regulated in brains in response to JEV infection (change fold ≥ 2.0, pvalue < 0.05). Unsupervised clustering (Figure 1{ref-type="fig"}) analysis of the expression profiles showed a distinct mRNA signature in both spleens and brains during JEV infection. To elucidate the correlation between gene expression pattern and JEV infection-induced biological processes, functional classification of mRNA transcripts and pathway analysis were performed. Differentially regulated genes in spleens of JEV-infected mice are involved in the biological processes such as cellular process, biological regulation and immune system process, etc (Figure 2A{ref-type="fig"}). And the significant pathways of differentially expressed genes are known to be involved in cytokine-cytokine receptor interaction, natural killer cell mediated cytotoxicity, antigen processing and presentation, and chemokine signaling, etc (Table 1{ref-type="table"}). While biological processes which showed differentially regulated genes in brains of JEV infected mice are cellular process, metabolic process, and biological regulation, etc (Figure 2B{ref-type="fig"}). And the significant pathways of differentially expressed genes in mouse brain are cytokine-cytokine receptor interaction, MAPK signaling, neuroactive ligand-receptor interaction, and toll-like receptor signaling, etc. (Table 2{ref-type="table"}).

    [image: Unsupervised hierarchical clustering of differentially expressed mRNAs. mRNA hybridization was performed with the use of 4 × 44 K Agilent Whole Mouse Genome Oligo Microarray. For each sample pair, the experiments were done with two independent hybridizations (Cy3 and Cy5 interchanging labeling). Genes that had ≥ |2|-fold change were identified as significantly differentially expressed. Differentially regulated genes were clustered using SAS (ShanghaiBio Analysis System) to identify significant gene expression patterns in spleens (A) and brains (B) of JEV-infected mice. Red indicates higher expression and green indicates lower expression in JEV-infected mice versus control. Black indicates no expression difference. The small figure represents color scales used in the cluster map.C indicates control group and V indicates viral-inoculated group. Each group contains 3 mice.] {#F1}

    [image: Enriched Gene Ontology terms in the biological process category among differentially expressed genes. After mRNA microarray assay, significantly enriched Gene Ontology analysis in the biological process category among differentially expressed genes (fold change ≥ 2.0) in spleens (A) and brains (B) of JEV-infected mice was performed by using SAS (ShanghaiBio Analysis System). Each color section represents a different biological process and the gene number enriched in this section was shown following the biological process name.] {#F2}

    Significant pathways of the differential expressed genes in spleens of JEV-infected mice.

    Pathway name No. of genes p-Value


    Antigen processing and presentation 9 0 Chemokine signaling pathway 13 0 Complement and coagulation cascades 7 0 Cytokine-cytokine receptor interaction 23 0 Natural killer cell mediated cytotoxicity 9 0 Classical Complement Pathway 3 1.00E-04 Complement Pathway 3 4.00E-04 Alternative Complement Pathway 2 0.0021 Granzyme A mediated Apoptosis Pathway 2 0.0036 Toll-like receptor signaling pathway 4 0.0071 Intestinal immune network for IgA production 3 0.009 CCR3 signaling in Eosinophils 2 0.0111 Caspase Cascade in Apoptosis 2 0.0121 NOD-like receptor signaling pathway 3 0.0121 MAPK signaling pathway 6 0.0168 ECM-receptor interaction 3 0.0232 Jak-STAT signaling pathway 4 0.0284 IFN gamma signaling pathway 1 0.0478 B Lymphocyte Cell Surface Molecules 1 0.0611 T cell receptor signaling pathway 3 0.069

    Significant pathways of the differential expressed genes in brains of JEV-infected mice.

    Pathway name No. of genes p-value


    Chemokine signaling pathway 19 0 Cytokine-cytokine receptor interaction 30 0 Jak-STAT signaling pathway 19 0 MAPK signaling pathway 19 0 NOD-like receptor signaling pathway 10 0 Purine metabolism 14 0 Toll-like receptor signaling pathway 13 0 IL-2 Receptor Beta Chain in T cell Activation 5 6.00E-04 Neuroactive ligand-receptor interaction 16 6.00E-04 NF-kB activation by Nontypeable Hemophilus influenzae 4 0.0012 Apoptosis 7 0.0023 Antigen processing and presentation 7 0.0037 IFN gamma signaling pathway 2 0.0082 Natural killer cell mediated cytotoxicity 8 0.011 T cell receptor signaling pathway 7 0.0123 IFN alpha signaling pathway 2 0.0156 FAS signaling pathway (CD95) 3 0.0173

    Genes with differential expression in spleens of JEV-infected mice

    In spleens of mice with JEV infection, 263 genes were detected to be significantly upregulated and 174 genes were downregulated (Table 3{ref-type="table"}). Genes with increased expression in spleens of JEV infected mice mainly fell into the function of immune response to viral infections. These include pro-inflammatory cytokine IFN-γ, IFN response transcription factor IRF7, IFN-induced proteins like IFIT1, IFITM3 and IFITM7, protein degradation gene ubiquitin-specific protease Usp29 and Usp18, apoptosis related genes granzymA, granzymeB, Porferin, and IMNB2, killer cell lectin-like receptors KLRC1, KLRC2 and KLRC3, and chemokines such as CXCL10, CXCL11, CCL12, CCL2 and CCL9. The marked increase in expression of these genes implies the occurrence of a strong antiviral protective response to JEV infection. The significantly downregulated genes are mainly involved in cell adhesion molecules such as monocyte/macrophage-lineage cell marker CD163, transmembrane cell surface receptor of Langerhans cells CD207, and ligand for myeloid cells receptor CD200. Evidence was also found for decreased expression of interferon transcription factor IRF6 and interleukin 7 receptor, which may contribute to JEV pathogenesis as well.

    Differentially-regulated genes of our interest in spleens of mice with JEV Infection

    Genbank Accession Gene symbol Gene description Fold change p-Value


    Up-regulated
    NM_177261 Kndc1 kinase non-catalytic C-lobe domain (KIND) containing 1 21.440 0.0252 NM_019494 Cxcl11 chemokine (C-X-C motif) ligand 11 19.752 0.0084 NM_013542 Gzmb granzyme B 6.202 0.0286 NM_031167 Il1rn interleukin 1 receptor antagonist (Il1rn), transcript variant 1 6.060 0.0015 AK157531 LOC629091 activated spleen cDNA, RIKEN full-length enriched library, clone:F830221E13 5.500 0.0154 NM_001033228 Itga1 integrin alpha 1 5.482 0.0308 NM_013584 Lifr leukemia inhibitory factor receptor 5.319 0.0109 NM_177923 H2-M10.2 histocompatibility 2, M region locus 10.2 5.276 0.0009 NM_008198 Cfb complement factor B 5.188 0.0019 NM_001005858 LOC667370 similar to interferon-induced protein with tetratricopeptide repeats 3 4.949 0.0459 NM_145153 Oas1f 2'-5' oligoadenylate synthetase 1F 4.619 0.0013 NM_011331 Ccl12 chemokine (C-C motif) ligand 12 4.539 0.0308 NM_027893 Pvrl4 poliovirus receptor-related 4 4.429 0.0352 NM_010741 Ly6c lymphocyte antigen 6 complex, locus C 4.287 0.0042 NM_010370 Gzma granzyme A 4.236 0.0010 NM_009152 Sema3a sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3A 4.132 0.0358 AF229257 Usp29 ubiquitin-specific processing protease 29 4.033 0.0093 NM_133871 Ifi44 interferon-induced protein 44 3.843 0.0053 NM_009912 Ccr1 chemokine (C-C motif) receptor 1 3.734 0.0013 BC025535 Fcgr1 Fc receptor, IgG, high affinity I 3.668 0.0096 NM_145226 Oas3 2'-5' oligoadenylate synthetase 3 3.531 0.0017 NM_008331 Ifit1 interferon-induced protein with tetratricopeptide repeats 1 3.433 0.0460 NM_021274 Cxcl10 chemokine (C-X-C motif) ligand 10 3.418 0.0307 NM_016850 Irf7 interferon regulatory factor 7 3.378 0.0083 NM_008530 Ly6f lymphocyte antigen 6 complex, locus F 3.313 0.0027 NM_011940 Ifi202b interferon activated gene 202B 3.296 0.0266 NM_145211 Oas1a 2'-5' oligoadenylate synthetase 1A 3.283 0.0082 NM_145227 Oas2 2'-5' oligoadenylate synthetase 2 3.178 0.0083 NM_144559 Fcgr4 Fc receptor, IgG, low affinity IV 3.069 0.0067 NM_027835 Ifih1 interferon induced with helicase C domain 1 2.940 0.0258 NM_008462 Klra2 killer cell lectin-like receptor, subfamily A, member 2 2.906 0.0001 NM_021792 Iigp1 interferon inducible GTPase 1 2.535 0.0232 L38281 Irg1 immune-responsive gene 1 2.496 0.0329 NM_008329 Ifi204 interferon activated gene 204 2.422 0.0290 NM_025378 Ifitm3 interferon induced transmembrane protein 3 2.401 0.0002 NM_021378 Klrc3 killer cell lectin-like receptor subfamily C, member 3 2.396 0.0063 NM_011909 Usp18 ubiquitin specific peptidase 18 2.333 0.0473 NM_011333 Ccl2 chemokine (C-C motif) ligand 2 2.314 0.0356 NM_028968 Ifitm7 interferon induced transmembrane protein 7 2.246 0.0014 NM_008337 Ifng interferon gamma 2.229 0.0054 NM_011338 Ccl9 chemokine (C-C motif) ligand 9 2.155 0.0065 NM_010653 Klrc2 killer cell lectin-like receptor subfamily C, member 2 2.131 0.0076 NM_009909 Il8rb interleukin 8 receptor, beta 2.077 0.0036 NM_010555 Il1r2 interleukin 1 receptor, type II 2.069 0.0248 NM_010652 Klrc1 killer cell lectin-like receptor subfamily C, member 1 2.025 0.0125 NM_011073 Prf1 perforin 1 (pore forming protein) 1.820 0.0326 NM_010722 Lmnb2 lamin B2 1.381 0.1976 Down-regulated
    NM_025989 Gp2 glycoprotein 2 (zymogen granule membrane) 0.048 0.0005 NM_053094 Cd163 CD163 antigen 0.060 0.0171 NM_177261 Kndc1 kinase non-catalytic C-lobe domain (KIND) containing 1 0.085 0.0070 NM_144943 Cd207 CD 207 antigen 0.159 0.0441 NM_010378 H2-Aa histocompatibility 2, class II antigen A, alpha 0.184 0.0055 NM_028135 Tmem163 transmembrane protein 163 0.211 0.0196 NM_007720 Ccr8 chemokine (C-C motif) receptor 8 0.242 0.0150 NM_016851 Irf6 interferon regulatory factor 6 0.261 0.0037 NM_013509 Eno2 enolase 2, gamma neuronal (Eno2) 0.276 0.0234 NM_011780 Adam23 a disintegrin and metallopeptidase domain 23 (Adam23) 0.281 0.0009 U96752 H2-Q1 major histocompability complex Q1b 0.282 0.0247 NM_008341 Igfbp1 insulin-like growth factor binding protein 1 0.289 0.0144 NM_010565 Inhbc inhibin beta-C (Inhbc) 0.304 0.0307 AK089361 AK089361 B6-derived CD11 +ve dendritic cells cDNA 0.307 0.0417 NM_013517 Fcer2a Fc receptor, IgE, low affinity II, alpha polypeptide 0.315 0.0318 NM_016808 Usp2 ubiquitin specific peptidase 2 (Usp2), transcript variant 1 0.319 0.0266 AK041838 Il7r interleukin 7 receptor 0.319 0.0256 NM_001033126 Cd27 CD antigen 27 (Cd27), transcript variant 1 0.326 0.0158 NM_009142 Cx3cl1 chemokine (C-X3-C motif) ligand 1 0.343 0.0227 NM_010215 Il4i1 interleukin 4 induced 1 0.387 0.0129 NM_207105 H2-Ab1 histocompatibility 2, class II antigen A, beta 1 0.520 0.0255 NM_033217 Ngfr nerve growth factor receptor (TNFR superfamily, member 16) 0.440 0.0110 AK041345 Xlr4a X-linked lymphocyte-regulated 4A 0.460 0.0074 NM_033042 Tnfrsf25 tumor necrosis factor receptor superfamily, member 25 0.465 0.0366 NM_198297 Trat1 T cell receptor associated transmembrane adaptor 1 0.476 0.0334 NM_011161 Mapk11 mitogen-activated protein kinase 11 0.478 0.0128 NM_007549 Blk B lymphoid kinase 0.483 0.0103 NM_010818 Cd200 Cd200 antigen 0.494 0.0156

    Genes with differential expression in brains of JEV-infected mice

    Compared to the expression after mock infection, 551 genes were detected to be significantly upregulated and 568 genes were downregulated in brains of JEV-infected mice (Table 4{ref-type="table"}). Consistent to the results of spleen, chemokines CCL2, CCL3, CCL4 and CXCL10, IFN response transcription factor IRF7, IFN-induced proteins like Ifit1, Ifit2 and Ifit3, protein degradation gene Usp18 were obviously upregulated, and CD163 and IRF6 showed decreased expression upon JEV infection. In addition, increased expression of IFN-inducible transcription factors STAT1 and STAT2, TNF-α induced protein TNFAIP3, apoptosis-related proteins caspase3 and caspase4, suppressors of cytokine signaling Socs1 and Socs3, pro-inflammatory cytokines IL-1 and IL-6, TLR7, as well as IFN response antiviral genes of OAS family were also observed in microarray analysis. These results suggested the occurrence of a strong inflammatory response in mouse brain.

    Differentially-regulated genes of our interest in brains of mice with JEV Infection.

    Genbank Accession Gene symbol Gene description Fold change p-Value


    Up-regulated
    NM_021274 Cxcl10 chemokine (C-X-C motif) ligand 10 1760.024 0.0020 NM_011333 Ccl2 chemokine (C-C motif) ligand 2 1387.794 0.0320 NM_013652 Ccl4 chemokine (C-C motif) ligand 4 336.804 0.0151 NM_010846 Mx1 myxovirus (influenza virus) resistance 1 229.188 0.0136 NM_145209 Oasl1 2'-5' oligoadenylate synthetase-like 1 209.863 0.0242 NM_011940 Ifi202b interferon activated gene 202B 201.477 0.0317 NM_008329 Ifi204 interferon activated gene 204 165.395 0.0404 NM_021792 Iigp1 interferon inducible GTPase 1 159.817 0.0168 NM_011337 Ccl3 chemokine (C-C motif) ligand 3 111.943 0.0429 NM_008176 Cxcl1 chemokine (C-X-C motif) ligand 1 107.659 0.0158 AK085407 Ifi44 interferon gamma inducible protein 44 91.009 0.0062 NM_010555 Il1r2 interleukin 1 receptor, type II 89.273 0.0297 NM_021893 Cd274 CD274 antigen 87.250 0.0337 NM_008330 Ifi47 interferon gamma inducible protein 47 83.552 0.0286 NM_172648 Ifi205 interferon activated gene 205 82.479 0.0416 NM_194336 Mpa2l macrophage activation 2 like 77.279 0.0464 NM_007609 Casp4 caspase 4, apoptosis-related cysteine peptidase 77.077 0.0451 NM_017466 Ccrl2 chemokine (C-C motif) receptor-like 2 74.783 0.0071 NM_008332 Ifit2 interferon-induced protein with tetratricopeptide repeats 2 65.247 0.0222 NM_011331 Ccl12 chemokine (C-C motif) ligand 12 65.192 0.0079 NM_033601 Bcl3 B-cell leukemia/lymphoma 3 53.003 0.0138 NM_029803 Ifi27 interferon, alpha-inducible protein 27 47.264 0.0403 NM_031168 Il6 interleukin 6 44.884 0.0106 NM_016850 Irf7 interferon regulatory factor 7 42.752 0.0463 NM_145211 Oas1a 2'-5' oligoadenylate synthetase 1A 41.831 0.0497 NM_011909 Usp18 ubiquitin specific peptidase 18 40.804 0.0052 NM_010501 Ifit3 interferon-induced protein with tetratricopeptide repeats 3 39.282 0.0008 NM_007707 Socs3 suppressor of cytokine signaling 3 36.912 0.0087 NM_008331 Ifit1 interferon-induced protein with tetratricopeptide repeats 1 32.115 0.0013 NM_013606 Mx2 myxovirus (influenza virus) resistance 2 31.018 0.0003 NM_011854 Oasl2 2'-5' oligoadenylate synthetase-like 2 29.655 0.0131 NM_009896 Socs1 suppressor of cytokine signaling 1 28.609 0.0492 NM_009140 Cxcl2 chemokine (C-X-C motif) ligand 2 24.678 0.0392 NM_010397 H2-T22 histocompatibility 2, T region locus 22 21.010 0.0473 NM_027835 Ifih1 interferon induced with helicase C domain 1 19.804 0.0233 NM_009397 Tnfaip3 tumor necrosis factor, alpha-induced protein 3 19.385 0.0300 NM_009283 Stat1 signal transducer and activator of transcription 1 18.134 0.0348 NM_001083925 Oas1b 2'-5' oligoadenylate synthetase 1B 17.574 0.0342 NM_008361 Il1b interleukin 1 beta 15.753 0.0043 NM_133211 Tlr7 toll-like receptor 7 9.880 0.0343 NM_027450 Glipr2 GLI pathogenesis-related 2 9.275 0.0405 NM_008562 Mcl1 myeloid cell leukemia sequence 1 9.054 0.0336 NM_029419 Apol3 apolipoprotein L 3 8.806 0.0165 NM_001008700 Il4ra interleukin 4 receptor, alpha 8.639 0.0360 NM_013730 Slamf1 signaling lymphocytic activation molecule family member 1 8.274 0.0435 NM_009841 Cd14 CD14 antigen 6.666 0.0034 NM_033541 Oas1c 2'-5' oligoadenylate synthetase 1C 6.596 0.0120 NM_009810 Casp3 caspase 3, apoptosis-related cysteine peptidase 2.119 0.0117 Down-regulated
    NM_053094 Cd163 CD163 antigen 0.066 0.0007 XM_898059 Cd209f CD209f antigen 0.088 0.0271 NM_026972 Cd209b CD209b antigen 0.132 0.0149 NM_033042 Tnfrsf25 tumor necrosis factor receptor superfamily, member 25 0.196 0.0288 NM_016708 Npy5r neuropeptide Y receptor Y5 (Npy5r) 0.242 0.0351 NM_019577 Ccl24 chemokine (C-C motif) ligand 24 (Ccl24) 0.302 0.0132 NM_008409 Itm2a integral membrane protein 2A 0.302 0.0075 AK042749 D230046B21Rik 7 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:A730020N04 0.311 0.0358 NM_030143 Ddit4l DNA-damage-inducible transcript 4-like 0.318 0.0004 NM_022723 Scube1 signal peptide, CUB domain, EGF-like 1 0.319 0.0400 AK144387 4732444A12Rik 21 days neonate cerebellum cDNA, RIKEN full-length enriched library, clone:G630051C23 0.319 0.0000 AK082652 Tmem44 transmembrane protein 44 0.324 0.0108 NM_175106 Tmem177 transmembrane protein 177 (Tmem177) 0.330 0.0346 NM_175564 Tmem169 transmembrane protein 169 0.336 0.0371 NM_027016 Tloc1 translocation protein 1 0.336 0.0276 NM_027163 Il1f8 interleukin 1 family, member 8 0.421 0.0267 NM_022986 Irak1bp1 interleukin-1 receptor-associated kinase 1 binding protein 1 0.422 0.0169 NM_016851 Irf6 interferon regulatory factor 6 0.447 0.0303 NM_145826 Il17re interleukin 17 receptor E (Il17re), transcript variant 1 0.477 0.0403

    Confirmation of microarray data by RT-qPCR

    To confirm the microarray hybridization results, quantitative RT-PCR was performed on eight selected differentially expressed mRNAs in mouse spleen and brain respectively. As shown in the RT-qPCR result of spleen, granzymA, granzymeB, Porferin, IRF7, IFN-γ, CXCL10, and ILIR2 were significantly upregulated, while CD163 was downregulated (Table 5{ref-type="table"}). Out of eight tested mRNAs in brains of mice infected with JEV, CCL2, CCL4, CXCL10, Casp3, Casp4, SOCS1 and SOCS3 showed increased expression, and CD163 was also found to have an obviously decreased expression (Table 5{ref-type="table"}). Although absolute values are not identical due to the different sensitivity between the techniques, all genes showed a well comparative expression pattern with microarray data.

    Comparison of expression changes of some selected genes between microarray and qRT-PCR

    Gene name Gene description Fold change


    Spleen
    Cxcl10 chemokine (C-X-C motif) ligand 10 3.418 3.375 (±1.065) Ifng interferon gamma 2.229 3.062 (±0.507) Gzmb granzyme B 6.202 7.285 (±0.311) Gzma granzyme A 4.236 3.815 (±0.127) Prf1 Porferin 1 1.820 2.287 (±0.643) Irf7 interferon regulatory factor 7 3.378 4.926 (±0.309) Il1r2 Interleukin 1 receptor, type II 2.069 2.078 (±0.105) Cd163 CD163 antigen 0.060 0.083 (±0.017) Brain
    Cxcl10 chemokine (C-X-C motif) ligand 10 1760.024 13.492 (±1.690) Ccl2 chemokine (C-C motif) ligand 2 1387.794 188.549 (±8.931) Ccl4 chemokine (C-C motif) ligand 4 336.804 61.007 (±3.735) Casp3 Caspase3, apoptosis-related cysteine peptidase 2.119 1.207 (±0.073) Casp4 caspase4, apoptosis-related cysteine peptidase 77.077 19.969 (±0.050) Socs1 suppressor of cytokine signaling 1 28.609 11.182 (±0.845) Socs3 suppressor of cytokine signaling 3 36.912 4.672 (±0.464) Cd163 CD163 antigen 0.066 0.065 (±0.012)

    Discussion

    Spleen is one of the major peripheral immunity organs and CNS is the ultimate infection target of JEV. Therefore, identification of the JEV-related host genes in spleens and brains of mice infected with JEV may be helpful for understanding of JEV pathogenesis. To this end, profiles of mRNA expression in both spleen and brain tissues of JEV-infected mice were analyzed systematically in this study.

    In mRNA profiling assay, we found chemokines like CCL2 and CXCL10 were significantly up-regulated in both mouse spleen and brain in response to JEV-infection, suggesting a strong inflammatory response of host. Monocyte chemoattractant protein-1 (MCP-1/CCL2) is one of the key chemokines that regulate migration and infiltration of monocytes/macrophages. It was involved in neurological disorders such as encephalitis-related neuronal death, where its levels were elevated in astrocytes leading to neuronal death [[@B13]]. Previous study has demonstrated that the WNV-infection stimulated the expression of CCL2 in mice livers, suggesting a consistent result to our study of JEV [[@B10]]. CXCL10 is also found to play a crucial role in the host defense response against various viral infection of the CNS by enhancing innate immune responses [[@B14],[@B15]], and our result of up-regulated CXCL10 mRNA has a good agreement with that was reported by Gupta et al. and Biswas et al. [[@B11],[@B12]].

    In addition, a strong IFN-pathway-related response was evident in mouse spleen and brain infected with JEV, with increased expression of IFN-γ, IFN response transcription factor IRF7, IFN-induced proteins IFIT1,IFITM3 and IFITM7 in spleen, and IRF7, IFN-inducible transcription factors STAT1 and STAT2, IFN-induced proteins IFIT1, IFIT2 and IFIT3 in brain, implying the occurrence of a protective response of host. Similar results were shown in previous reports as the upregulation of IFN-γ, STAT1 and STAT2 in JEV-infected mice brain [[@B12]], and increased expression of STAT1 and IFIT3 in JEV-infected N2A cells [[@B11]]. The reason why no increase in expression of IFN-γ was found in brains of JEV-infected mice in our study may be related to the difference of time points with Biswas' study [[@B11]]. IRF7 is activated in the presence of double stranded RNA following virus infection, which is functional as one of the regulators of the IFN-α/β gene promoter and the IFN-α/β responsive genes to create an antiviral state [[@B16]]. The increased expression of IRF7 has also been demonstrated in WNV infected mice, but wasn't found in JEV infected cells [[@B17],[@B18]]. This may be due to the different signal pathways between intact host and cell culture.

    Pore-forming protein perforin and the family of granzymes have been demonstrated to form an antiviral arsenal central to the function of cytotoxic T lymphocyte (CTL) and natural killer (NK) cells [[@B19]-[@B21]]. After JEV infection, pro-apoptotic genes found to have significant enhancement in mouse spleen, including porferin, granzyme A and granzymeB, which suggested a strong cytotoxic response against JEV infection. The consistent result as increased expression of granzyme A and B was also shown in the report about WNV infection [[@B17]]. Granzyme B is the most characterized granyzme which plays an important role in inducing apoptosis, and it is generally accepted that granzyme A can trigger a distinct nonapoptotic form of cell death [[@B22]]. The high expression of granzyme A and B in spleen could help clear virus infection, but may also involve lymphocyte injury. The upregulation of apoptosis-related proteins Caspase3 and 4 were also detected in brains of mice infected with JEV, indicating an inflammation-related neuronal apoptosis. Caspase 3 is an effector caspase that function as a central regulator of apoptosis. It has been reported that JEV infection triggers apoptosis in different cells, such as baby hamster kidney BHK-21 cells, mouse neuroblastoma N18 cells, human neuronal NT-2 cells, and human medulloblastoma cells, resulting in caspase 3 activation [[@B23]-[@B25]]. The function of caspase 4 is not fully known, but it is believed to be an inflammatory caspase, with a role in the immune system [[@B26]].

    Pro-inflammatory cytokines like IL-1 and IL-6 were found to have increased expression in the brain, which was consistent with the results of the studies on DV and WNV [[@B8],[@B17]]. IL-1α and IL-1β has been known to form an important part of the inflammatory response of the body against infection. IL-6 together with IL-1 and TNF-α acts as an endogenous pyrogen by causing fever following viral infections [[@B27]]. It's also associated with an unfavorable outcome following yellow fever virus infection [[@B28]]. Evidence suggests that circulating IL-6 can activate CNS mechanisms resulting in the development of the febrile response during disease [[@B29]]. Upregulation of IL-1 and IL-6 in brain may thus be protective against harmful JEV infection, but also have a pathogenic role in CNS.

    The 2', 5'-oligoadenylate synthetase (OAS) and its downstream effector RNase L play important roles in host defense against virus infection. The OAS1b protein has been described as a flavivirus resistance factor, and OASl1 as a WNV-resistance factor in wild mice because a truncated version of the protein is expressed in laboratory mice which are susceptible to infection [[@B30]-[@B32]]. Human OAS1 p42/p46 and OAS3 p100 are likely to contribute to host defense against DEN infection and play a role in determining the outcomes of DEN disease severity [[@B33]]. Further, the activated expression of OAS2 has been demonstrated in mouse brain in response to JEV infection [[@B34]]. In present study, there was increased expression of various members of the OAS family in the brains of JEV-infected mice, including OAS1a, OAS1b, OAS1c, OAS1e, and OAS2. Therefore, the ability of these proteins to protect against JEV infection should also be further studied.

    The significant downregulation of CD163 was detected both in mouse spleen and brain in response to JEV infection. CD163 is a novo identified marker for perivascular macrophages in humans, monkeys, and mice. And previously studies have found that perivascular CD163 expression is upregulated and the number of CD163-positive cells increases in HIV and SIV encephalitis (HIVE and SIVE) brains [[@B35],[@B36]]. However, CD163 is not a "classical" activation marker, because peripheral blood monocytes and most tissues macrophages of normal uninfected controls all express it and because in vitropro-inflammatory stimuli largely down-regulate its expression. These findings suggest that CD163 expression is regulated in association with a certain stage of differentiation. Here, our results showed a downregulated CD163 mRNA level in response to acute JEV infection, which probably suggested a decreased number of activated perivascular macrophages resulted by inflammatory disorder-related apoptosis response.

    Conclusions

    In summary, our findings suggested that JEV infection resulted in significant changes in the expression of multiple genes in mouse spleen and brain, including inflammatory cytokines, chemokines, IFN inducible genes, IFN regulators, and apoptosis related genes, etc. These genes may play a critical role on antiviral response of host against JEV infection but could also contribute to the pathogenesis of JEV resulting in encephalitis. The mRNA profile obtained by microarray analysis in this study may provide a foundation for future investigation of JEV pathogenesis and therapeutic method.

    Methods

    Virus production

    JEV wide type strain P3 was propagated in brains of suckling mice and titered in BHK-21 cells which was grown and maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% heated-inactivated fetal bovine serum (FBS, Hyclone, Logan, UT, USA), 100 g/ml streptomycin and 100 IU/ml penicillin (Sigma-Aldrich, MO, USA) at 37°C with 5% CO2.

    Virus infection of mice

    Four-weeks-old naive female BALB/c mice were purchased from Wuhan Institute of Biologic Products (Hubei Province, China) and inoculated subcutaneously (s.c.) with 5 × 10^6^PFU of JEV P3 strain. Dilutions were performed in serum-free DMED and experimental controls were mock injected with diluent. A part of JEV-infected mice were sacrificed at day 3 post-inoculation (the day before the neurological symptoms appeared), and spleens were harvested. The left mice were sacrificed at day 6 post-inoculation (the day before the mice started to die), and brains of mice were harvested. Spleen and brain homogenate was made in DMEM for RNA extraction.

    Microarrays and bioinformatics

    The total RNA was isolated from mouse spleens and brains respectively with trizol reagent (Invitrogen) for mRNA Microarray. mRNA hybridization was performed by shanghaiBio Corporation (shanghai, China) with the use of 4 × 44 K Agilent Whole Mouse Genome Oligo Microarray (total 41,174 oligo probes from 41,174 mouse genes). For each sample pair, the experiments were done with two independent hybridizations (Cy3 and Cy5 interchanging labeling). Hybridized arrays were scanned at 5 μm resolution on an Agilent DNA Microarray Scanner (Model G2565BA). Data extraction from images was done by using Agilent Feature Extraction software. Hierarchical cluster, gene ontology and pathway analysis were analyzed by using SAS (ShanghaiBio Analysis System).

    Quantitative real-time RT-PCR (RT-qPCR)

    For selected mRNA RT-qPCR, total RNA from the same samples used in microarray analysis was tested by using ABI 7500 FAST real-time PCR system. PCR primers were designed with Primer Express 2.0 software (Invitrogen). Results are shown as fold change. For mRNA RT-qPCR, experiments were carried out with the PrimerScript RT reagent Kit (TaKaRa) and SYBR Green Realtim PCR Master Mix (TaKaRa) according to manufacture's instruction. The housekeeping gene GHDAP was used for standardization of the initial RNA content of a sample. Relative changes of gene expression were calculated by the following formula, and the data are represented as fold upregulation/downregulation. fold change = 2^-ΔΔCt^, whereΔΔCt =(Ct of gene of interest, treated -Ct of HK gene, treated)-(Ct of gene of interest, control-Ct of HK gene, control), Ct is the threshold cycle number and HK is the house keeping gene.

    Statistical analysis

    Each gene in each infection group was subjected to a Student's t test to detect large expression differences relative to the mock-infected group. p-values <0.05 were considered to be statistically significant.

    Competing interests

    The authors declare that they have no competing interests.

    Authors' contributions

    YY and JY carried out most of the experiments and wrote the manuscript. XY, RJ participated part of experiments. HC and SC conceived of the study, participated in its design and coordination, and revised the manuscript. All authors read and approved the final manuscript.

    Acknowledgements

    This work was supported by the 973 Project of China (No. 2010CB530100), Transregional Collaborative Research Centre TRR 60 and PCSIRT (IRT0726).

  2. Assistant

    Thank you for providing the detailed text. From your input, I will generate synthetic data that captures both System 1 and System 2 thinking, as well as creativity and metacognitive reflection. Here’s how this data will be organized:

    [sys1] Quick Overview: The text presents research on Japanese encephalitis virus (JEV), detailing its impact on the nervous system and immune response in infected mice. Researchers used DNA microarray analyses and RT-qPCR to explore gene expression in the spleen and brain tissues post-infection. Key findings include notable changes in inflammatory and immune response-related gene expression.

    [end sys1]

    [sys2]

    2.1 Understand the Problem: The challenge is to understand how JEV affects gene expression in mouse tissues to clarify pathogenesis and develop potential treatments.

    Reflection: "What do I understand about JEV's influence on spleen and brain tissues? How might these changes relate to symptoms of encephalitis?"

    Creative Perspective: "Is there a novel connection between the gene expression changes and disease outcomes, like specific pathways, which haven’t been fully explored yet?"

    2.2 Analyze the Information: Gene expression profiling reveals that numerous genes related to immune response, inflammation, and apoptosis are differentially expressed during JEV infection.

    Reflection: "Am I adequately considering the biosystem-wide influence of JEV? What assumptions about viral pathogenesis might need re-evaluation?"

    Creative Perspective: "Could the interplay between upregulated cytokine genes uncover new therapeutic targets or hint at unexpected disease mechanisms?"

    2.3 Generate Hypotheses:

    1. Macrophages play a central role in JEV CNS penetration. (Confidence: 0.7, Creative: 0.5)
    2. JEV-induced cytokines drive both protective immunity and neuropathology. (Confidence: 0.8, Creative: 0.6)
    3. Alterations in IFN pathways could hint at broader antiviral defense limitations in mice. (Confidence: 0.6, Creative: 0.7)
    4. Specific chemokines may provide therapeutic targets to mitigate CNS inflammation. (Confidence: 0.5, Creative: 0.8)
    5. Downregulation of CD163 may have implications for JEV immune evasion. (Confidence: 0.6, Creative: 0.7)
    6. Enhanced expression of apoptotic genes could indicate potential for therapeutic modulation. (Confidence: 0.7, Creative: 0.5)
    7. The interplay of cytokine cascades might result in unanticipated long-term immune modulation. (Confidence: 0.5, Creative: 0.9)
    8. Cross-species analysis of OAS gene family might highlight crucial resistance mechanisms. (Confidence: 0.6, Creative: 0.7)
    9. IFN pathway changes may reflect a broader pattern observed in flaviviruses. (Confidence: 0.7, Creative: 0.5)
    10. Neuro-inflammatory responses mirror those of other encephalitis-inducing viruses. (Confidence: 0.8, Creative: 0.4)

    Reflection: "Have I overlooked any key pathways or potential interaction effects?"

    Creative Perspective: "What innovative therapeutic approach might emerge by reevaluating the role of identified cytokines and apoptotic factors?"

    2.4 Anticipate Future Steps and Obstacles: Objective: Anticipate challenges in translating mouse model findings to human therapy and broader viral research applications.

    Reflection: "What might be the limitations of using mouse models exclusively?"

    Creative Perspective: "How might emerging technologies, like CRISPR-based gene editing, aid in testing these hypotheses?"

    [end sys2]

    [sys1] Strategic Approach: Consider extending research to other animal models to validate findings. Explore CRISPR techniques for verifying gene function roles in JEV pathogenesis. Partner with cross-disciplinary teams for comprehensive therapeutic target validation.

    [end sys1]